anti-MMP9 mAb (Gilead/Cedars-Sinai Medical Center)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameanti-MMP9 mAb (Gilead/Cedars-Sinai Medical Center)
Drug Alias Nameanti-matrix metalloproteinase 9 mAb (Gilead/Cedars-Sinai Medical Center)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionMatrix metalloproteinase 9 inhibitors
TargetsMatrix metalloproteinase 9
Therapy Area/IndicationsIdiopathic Pulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences IncCedars-Sinai Medical Center
Active IndicationsN/A
Inactive IndicationsIdiopathic Pulmonary Fibrosis

Other Information

ATC CodeN/A
Related LinksN/A